Higashiyama Masahiro, Motoi Noriko, Yotsukura Masaya, Yoshida Yukihiro, Nakagawa Kazuo, Yagishita Shigehiro, Shirasawa Masayuki, Yoshida Tatsuya, Shiraishi Kouya, Kohno Takashi, Ohe Yuichiro, Watanabe Shun-Ichi
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan.
Pathol Int. 2023 May;73(5):188-197. doi: 10.1111/pin.13316. Epub 2023 Mar 9.
Ciliated muconodular papillary tumor/bronchiolar adenoma (CMPT/BA) is a recently introduced benign lung tumor. It remains unclear whether CMPT/BA is associated with a specific type of lung cancer (LC). We studied the clinicopathological characteristics and genetic profiles of the coexisting primary LC and CMPT/BA (LCCM) cases. We identified eight LCCM (0.4%) from the resected Stage 0-III primary LC (n = 1945). The LCCM cohort was male-dominant (n = 8), elderly (median 72 years old), and most were smokers (n = 6). In addition to the adenocarcinoma (n = 8), we detected two squamous cell carcinomas and one small cell carcinoma-in some cases, multiple cancer. The target sequence/whole exome sequence (WES) revealed no shared mutations between CMPT/BA and LC. One exceptional case was invasive mucinous adenocarcinoma harboring an HRAS mutation (I46N, c.137T>A), but it was likely to be a single nucleotide polymorphism based on variant allele frequency (VAF). Other driver mutations in LC included EGFR (InDel, n = 2), BRAF(V600E) (n = 1), KRAS (n = 2), GNAS (n = 1), and TP53 (n = 2). BRAF(V600E) was the most frequent mutation in CMPT/BA (60%). In contrast, LC showed no specific trend in driver gene mutations. In conclusion, our study revealed differences in the gene mutation profiles of CMPT/BA and LC in coexisting cases, suggesting mostly independent clonal tumorigenesis of CMPT/BA from LC.
纤毛黏液结节性乳头状肿瘤/细支气管腺瘤(CMPT/BA)是一种最近新发现的良性肺肿瘤。CMPT/BA是否与特定类型的肺癌(LC)相关仍不清楚。我们研究了共存的原发性LC和CMPT/BA(LCCM)病例的临床病理特征和基因图谱。我们从1945例切除的0-III期原发性LC中鉴定出8例LCCM(0.4%)。LCCM队列以男性为主(n = 8),患者年龄较大(中位年龄72岁),且大多数为吸烟者(n = 6)。除腺癌外(n = 8),我们还检测到2例鳞状细胞癌和1例小细胞癌,在某些情况下为多原发癌。靶向序列/全外显子组测序(WES)显示CMPT/BA和LC之间没有共同突变。有一个例外病例是携带HRAS突变(I46N,c.137T>A)的浸润性黏液腺癌,但根据变异等位基因频率(VAF),这可能是一个单核苷酸多态性。LC中的其他驱动基因突变包括EGFR(插入缺失,n = 2)、BRAF(V600E)(n = 1)、KRAS(n = 2)、GNAS(n = 1)和TP53(n = 2)。BRAF(V600E)是CMPT/BA中最常见的突变(60%)。相比之下,LC在驱动基因突变方面没有特定趋势。总之,我们的研究揭示了共存病例中CMPT/BA和LC基因突变谱的差异,表明CMPT/BA与LC大多是独立的克隆性肿瘤发生。